Sparta Pharmaceuticals Inc. announces patent approval from the United States Patent and Trademark Office.HORSHAM, Pa.--(BUSINESS WIRE)--July 1, 1997--Sparta Pharmaceuticals Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : SPTA SPTA Spectrin, Alpha SPTA Silicon Prairie Technology Association SPTA Southern Pressure Treaters Association (Gulf Shores, Alabama) SPTA Saint Petersburg Telegraph Agency (PTA predecessor 1904-1914) , SPTAU, SPTAW, SPTAZ and SPTAL) announced that the United States Patent and Trademark Office The United States Patent and Trademark Office (PTO or USPTO) is an agency in the United States Department of Commerce that provides patent protection to inventors and businesses for their inventions, and trademark registration for product and intellectual property has granted United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. Patent No. 5,637,479 submitted by Dr. Harvey Rubin and colleagues of The University of Pennsylvania (body, education) University of Pennsylvania - The home of ENIAC and Machiavelli. http://upenn.edu/. Address: Philadelphia, PA, USA. (Penn). The patent is entitled, "A Method of Modulating DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. Binding Activity of Recombinant alpha-1-Antichymotrypsin and Other Serine Protease Inhibitors." This is the sixth United States patent to be granted through Sparta's collaboration with Penn. Through a Sparta funded grant, Rubin, who is a scientific advisor to the company, has created a new class of recombinant modified human proteins that are specific serine protease inhibitors. The company has an exclusive license to over 60 compounds covered in the six U.S. patents issued to Penn; international patents are pending. According to Dr. Jerry B. Hook, Sparta's president and chief executive officer, "The issuance of this patent will further enhance Sparta's strong proprietary position regarding recombinant serine protease inhibitors, their production and use." The company believes this recombinant serine protease inhibitor program has the potential to be successful in treating serious conditions where uncontrolled inflammatory responses may have fatal consequences including: cardiovascular disorders, stroke, lung inflammation and pancreatitis. This press release contains certain forward-looking statements within the meaning of the "safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Such statements are made based on management's current expectations and beliefs, and actual results may vary from those currently anticipated based upon a number of factors, including uncertainties inherent in the drug development process, including clinical trials. The company undertakes no obligation to release publicly any revisions which may be made to reflect events or circumstances after the date hereof. Sparta is a development stage pharmaceutical company engaged in the business of acquiring rights to, and developing for commercialization, technologies and drugs for the treatment of a number of life threatening diseases, including cancer, cardiovascular disorders and inflammation. The company has focused on acquiring compounds that have been previously tested in humans and animals and technologies that may improve the delivery or targeting of previously tested, and in some cases marketed, anticancer agents. Sparta's foundation in cancer chemotherapy has been augmented by the addition of new technology in the rapidly expanding field of serine protease inhibitors. Serine protease inhibitors have wide applications in diverse fields such as inflammation, reperfusion injury reperfusion injury damage to renal blood vessels during periods of hypotension does not become apparent until reperfusion occurs in the recovery stage of the vascular incident. and stroke. CONTACT: Sparta Pharmaceuticals Inc., Horsham Jerry B. Hook, Ph.D., president/CEO, 215/442-1700, ext. 205 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion